These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35915495)

  • 21. Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in South African children: a case-control study.
    Cohen C; von Mollendorf C; de Gouveia L; Lengana S; Meiring S; Quan V; Nguweneza A; Moore DP; Reubenson G; Moshe M; Madhi SA; Eley B; Hallbauer U; Finlayson H; Varughese S; O'Brien KL; Zell ER; Klugman KP; Whitney CG; von Gottberg A;
    Lancet Glob Health; 2017 Mar; 5(3):e359-e369. PubMed ID: 28139443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence and Estimated Vaccine Effectiveness Against Hospitalizations for All-Cause Pneumonia Among Older US Adults Who Were Vaccinated and Not Vaccinated With 13-Valent Pneumococcal Conjugate Vaccine.
    Hsiao A; Hansen J; Timbol J; Lewis N; Isturiz R; Alexander-Parrish R; McLaughlin JM; Gessner BD; Klein NP
    JAMA Netw Open; 2022 Mar; 5(3):e221111. PubMed ID: 35302634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the effectiveness of pneumococcal conjugate vaccine for children in Korea with high vaccine coverage using a propensity score matched national population cohort.
    Sohn S; Hong K; Chun BC
    Int J Infect Dis; 2020 Apr; 93():146-150. PubMed ID: 31982620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study.
    Whitney CG; Pilishvili T; Farley MM; Schaffner W; Craig AS; Lynfield R; Nyquist AC; Gershman KA; Vazquez M; Bennett NM; Reingold A; Thomas A; Glode MP; Zell ER; Jorgensen JH; Beall B; Schuchat A
    Lancet; 2006 Oct; 368(9546):1495-502. PubMed ID: 17071283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Direct effect of 10-valent conjugate pneumococcal vaccination on pneumococcal carriage in children Brazil.
    Andrade AL; Ternes YM; Vieira MA; Moreira WG; Lamaro-Cardoso J; Kipnis A; Cardoso MR; Brandileone MC; Moura I; Pimenta FC; da Gloria Carvalho M; Saraiva FO; Toscano CM; Minamisava R
    PLoS One; 2014; 9(6):e98128. PubMed ID: 24892409
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospital-treated pneumonia among people aged ≥65 years: a retrospective case-control study.
    Leventer-Roberts M; Feldman BS; Brufman I; Cohen-Stavi CJ; Hoshen M; Balicer RD
    Clin Infect Dis; 2015 May; 60(10):1472-80. PubMed ID: 25669354
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of 13-pneumococcal conjugate vaccine (PCV13) against invasive pneumococcal disease in children in the Dominican Republic.
    Tomczyk S; Lessa FC; Sánchez J; Peña C; Fernández J; Gloria Carvalho M; Pimenta F; Cedano D; Whitney CG; Verani JR; Coradin H; Garib Z; De Oliveira LH; Feris-Iglesias J
    BMC Infect Dis; 2018 Apr; 18(1):152. PubMed ID: 29609548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccine effectiveness of the 7-valent and 13-valent pneumococcal conjugate vaccines in Canada: An IMPACT study.
    Ricketson LJ; Bettinger JA; Sadarangani M; Halperin SA; Kellner JD;
    Vaccine; 2022 Apr; 40(19):2733-2740. PubMed ID: 35351324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age.
    Lucero MG; Dulalia VE; Nillos LT; Williams G; Parreño RA; Nohynek H; Riley ID; Makela H
    Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004977. PubMed ID: 19821336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
    Andrews N; Kent A; Amin-Chowdhury Z; Sheppard C; Fry N; Ramsay M; Ladhani SN
    Vaccine; 2019 Jul; 37(32):4491-4498. PubMed ID: 31272872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on serotype 19A invasive pneumococcal disease.
    Principi N; Esposito S
    Expert Rev Vaccines; 2015; 14(10):1359-66. PubMed ID: 26289973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
    Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
    Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada.
    Deceuninck G; De Serres G; Boulianne N; Lefebvre B; De Wals P
    Vaccine; 2015 May; 33(23):2684-9. PubMed ID: 25887086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of ten-valent pneumococcal conjugate vaccine on pneumonia in Finnish children in a nation-wide population-based study.
    Palmu AA; Rinta-Kokko H; Nohynek H; Nuorti JP; Kilpi TM; Jokinen J
    PLoS One; 2017; 12(3):e0172690. PubMed ID: 28249015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Declines in Pneumonia and Meningitis Hospitalizations in Children Under 5 Years of Age After Introduction of 10-Valent Pneumococcal Conjugate Vaccine in Zambia, 2010-2016.
    Mpabalwani EM; Lukwesa-Musyani C; Imamba A; Nakazwe R; Matapo B; Muzongwe CM; Mufune T; Soda E; Mwenda JM; Lutz CS; Pondo T; Lessa FC
    Clin Infect Dis; 2019 Sep; 69(Suppl 2):S58-S65. PubMed ID: 31505628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Invasive disease potential of Streptococcus pneumoniae serotypes before and after 10-valent pneumococcal conjugate vaccine introduction in a rural area, southern Mozambique.
    Massora S; Lessa FC; Moiane B; Pimenta FC; Mucavele H; Chaúque A; Cossa A; Verani JR; Tembe N; da Gloria Carvalho M; Muñoz-Almagro C; Sigaúque B
    Vaccine; 2019 Dec; 37(51):7470-7477. PubMed ID: 31575493
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Indirect cohort analysis of 10-valent pneumococcal conjugate vaccine effectiveness against vaccine-type and vaccine-related invasive pneumococcal disease.
    Verani JR; Domingues CM; de Moraes JC;
    Vaccine; 2015 Nov; 33(46):6145-8. PubMed ID: 26469718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real world impact of 13vPCV in preventing invasive pneumococcal pneumonia in Australian children: A national study.
    Homaira N; Strachan R; Quinn H; Beggs S; Bhuiyan M; Bowen A; Fawcett LK; Gilbert GL; Lambert SB; Macartney K; Marshall HS; Martin Md AC; McCallum G; McCullagh A; McDonald T; Selvadurai H; McIntyre P; Oftadeh S; Ranganathan PhD S; Saunders T; Suresh S; Wainwright C; Wilson A; Wong M; Jaffe A; Snelling T
    Vaccine; 2023 Jan; 41(1):85-91. PubMed ID: 36400662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pneumonia Prevention during a Humanitarian Emergency: Cost-effectiveness of Haemophilus Influenzae Type B Conjugate Vaccine and Pneumococcal Conjugate Vaccine in Somalia.
    Gargano LM; Hajjeh R; Cookson ST
    Prehosp Disaster Med; 2015 Aug; 30(4):402-11. PubMed ID: 26061190
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of ten-valent pneumococcal conjugate vaccine introduction on pneumonia hospital admissions in Fiji: a time-series analysis.
    Reyburn R; Tuivaga E; Nguyen CD; Ratu FT; Nand D; Kado J; Tikoduadua L; Jenkins K; de Campo M; Kama M; Devi R; Rafai E; Weinberger DM; Mulholland EK; Russell FM
    Lancet Glob Health; 2021 Jan; 9(1):e91-e98. PubMed ID: 33227258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.